Vicore Pharma AB

ACTIVE

Argongatan 2D, Mölndal, Västra Götaland, Swedenvicorepharma.comSubsidiary11–50 employeesEstablished: 2009-01-01

Clinical Trials

8 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2009

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

40.0%

Phase 1

36.0%

Not Applicable

8.0%

Phase 2/3

4.0%

Phase 3

4.0%

Trial Status Distribution

Active, not recruiting

32.0%

Completed

48.0%

Recruiting

20.0%

Clinical Trials

Trials sponsored by this organization (25)

A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers

Phase 1

Recruiting

May 202624 participants

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Phase 2

Active, not recruiting

interventional

Dec 2024378 participants

A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes

Phase 1

Completed

interventional

Mar 202311 participants

A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers

Phase 1

Completed

interventional

Mar 202319 participants

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

Phase 1

Completed

interventional

Jun 202280 participants

Effect of C21 on Forearm Blood Flow

Phase 1

Completed

interventional

Apr 20225 participants

Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF

Not Applicable

Completed

interventional

Apr 2022119 participants

The study of C21 in hospitalised subjects with COVID-19 infection not requiring mechanical ventilation

Phase 2/3

Active, not recruiting

interventional

Sep 2021600 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations